Latest news newssearch boxGO All Ad hoc Other 23 May 2022 Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension 26 Apr 2022 Idorsia announces financial results for the first quarter 2022 – first product launched, second in the starting blocks 14 Apr 2022 Idorsia holds its Annual General Meeting of Shareholders 03 Mar 2022 Idorsia issues Notice of the 2022 Annual General Meeting of Shareholders 25 Feb 2022 QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder 08 Feb 2022 Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025 24 Jan 2022 Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical Development 20 Jan 2022 Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg 10 Jan 2022 Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia 13 Dec 2021 Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study 01 Nov 2021 Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus 27 Oct 2021 Johnson & Johnson partially converts its convertible loan 26 Oct 2021 Idorsia announces financial results for the third quarter 2021 – company progressing and launch preparations in key markets well underway 11 Oct 2021 Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease 29 Jul 2021 Application of Jean-Paul and Martine Clozel regarding the exemption from the offer obligation in relation to Idorsia Ltd 28 Jul 2021 Idorsia launches the offering of convertible bonds to fund the development of the company into a leading biopharmaceutical company 27 Jul 2021 Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company 28 Jun 2021 Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction 25 May 2021 European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features 12 May 2021 Idorsia holds its Annual General Meeting of Shareholders 1 2
Ad hoc announcements pursuant to Art. 53 LR Ad hoc announcements pursuant to Art. 53 LR have been classified from 2021 onwards. A full archive of press releases can be found under the "All" tab.